Association between chronic pain medications and the severity and mortality of COVID-19
| Autor: | María Luz Padilla Del Rey, Leticia Gómez-Caro Álvarez Palencia, Víctor Mayoral Rojals, Dolores Ochoa Mazarro, Miren Revuelta Rizo, Luz Cánovas Martínez, Agustín Mendiola de la Osa, Concepción Pérez Hernández, Ana Peiró Perió, María Jesús Domínguez Bronchal, Gustavo Fabregat-Cid, Cesar Margarit Ferri, José Cid Calzada, Andrés Ancor Serrano Afonso, Inmaculada Failde Martínez, Elena Rojo Rodríguez, Teresa Aberasturi Fueyo, Antonio Montes Pérez, Manuel Herrero Trujillano, Manuel Román Martínez, María José Hernández-Cádiz, Pablo López Pais, Manuel Mareque Ortega, Manuel José Muñoz Martinez |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty Multivariate analysis Disease Severity of Illness Index COVID-19 (Malaltia) Young Adult coronavirus disease 2019 Internal medicine Severity of illness Mortalitat medicine Humans Pain Management non-steroidal anti-inflammatory drugs Young adult Analgesics glucocorticoids SARS-CoV-2 business.industry Mortality rate Chronic pain COVID-19 opioids General Medicine Odds ratio medicine.disease Dolor crònic Epidemiologic Research Design analgesics Population study Female Chronic Pain chronic pain business |
| Zdroj: | MEDICINE r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante r-FIHGUV. Repositorio Institucional de Producción Científica de la Fundación de Investigación del Hospital General de Valencia |
| ISSN: | 1536-5964 0025-7974 |
| Popis: | In patients with coronavirus disease 2019 (COVID-19) infection, common drugs may exacerbate symptoms and negatively impact outcomes. However, the role of chronic medications on COVID-19 effects remains poorly understood. We hypothesized that certain chronic pain medications would influence outcomes in patients with COVID-19. The main aim is to assess the effect of these medications on the course of the disease in COVID-19 patients. Secondary aims are to compare disease severity and outcomes in patients with COVID-19 receiving chronic treatment with analgesics or other medications versus untreated patients and to determine prevalence of chronic pain medications in specific subgroups of hospitalized patients for COVID-19. Multicenter case-population study in 15 care centers for patients =18 years of age diagnosed and hospitalized with COVID-19. Controls will include patients treated at participating centers for chronic pain during the six-month period prior to March 15th, 2020. Each case will be age- and sex-matched to 10 controls. Patients will be grouped according to disease severity criteria. The primary outcome measures in patients admitted for COVID-19 will be: 1. statistical association between chronic pain medication and disease severity; 2. association between chronic pain treatment and survival. Secondary outcome measures include: 1. prevalence of chronic pain medications in patients with COVID-19 by age and sex; 2. prevalence of chronic pain medications in patients with COVID-19 vs controls. Patients and controls will be paired by age, sex, and geographic residence. Odds ratios with 95% confidence intervals will be calculated to determine the association between each drug and clinical status. Univariate and multivariate analyses will be performed. This is a study protocol. Data is actually being gathered and results are yet not achieved. There is no numerical data presented, so the conclusions cannot be considered solid at this point. Pain medications are likely to influence severity of COVID-19 and patient survival. Identifying those medications that are most closely associated with severe COVID-19 will provide clinicians with valuable data to guide treatment and reduce mortality rates and the long-term sequelae of the disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|